<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515084</url>
  </required_header>
  <id_info>
    <org_study_id>CHB 10-03</org_study_id>
    <nct_id>NCT02515084</nct_id>
  </id_info>
  <brief_title>Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma</brief_title>
  <acronym>THYRIRMTEP</acronym>
  <official_title>Preliminary Study of the Interest of Diffusion-weighted Magnetic Resonance Imaging in the Early Detection of Differentiated Thyroid Carcinoma Cervical Recurrence. Comparison with18F-FDG PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the concordance between the 18F-PET/CT under&#xD;
      thyrotropin stimulation and the diffusion-weighted Magnetic Resonance Imaging, in the&#xD;
      detection of residual mass in 40 patients with partial response or relapsed differentiated&#xD;
      thyroid carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The schedule and the procedures of the study are the following ones :&#xD;
&#xD;
        -  Baseline evaluation :&#xD;
&#xD;
             -  Clinical examination with neck echography after rhTSH stimulation&#xD;
&#xD;
             -  Normal whole body scan&#xD;
&#xD;
        -  First visit (inclusion):&#xD;
&#xD;
           18F-FDG PET/CT DW-MRI of the neck if possible performed shortly after the PET CT or&#xD;
           within following days&#xD;
&#xD;
        -  Following visits: at 6 months and 12 months&#xD;
&#xD;
             -  DW-MRI of the neck performed shortly after the PET CT or within following days.&#xD;
&#xD;
             -  Ultrasonography guided fine needle aspiration for cytology for detection of&#xD;
                cervical metastases and identifying thyroglobuline in the needle washout fluid if&#xD;
                needed and in case of positivity of either PET or DW-MRI exams.&#xD;
&#xD;
             -  Histological assessment of biopsies if performed&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Report of positive or negative results of detection of recurrent lesions from both dw-MRI and 18F-FDG PET/CT. data will be reported extensively and descriptively.</measure>
    <time_frame>1 year</time_frame>
    <description>To assess concordance between FDG PET-CT scan and MRI in detection of cervical residual masses in 40 patients in Partial Response or in relapse cervical well-differentiated thyroid carcinoma</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Thyroid Cancer</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>18F-FDG-PET and dw-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the inclusion, both all patients, a 18F-FDG-PET/CT and a dw-MRI will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET</intervention_name>
    <description>A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma</description>
    <arm_group_label>18F-FDG-PET and dw-MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI imaging</intervention_name>
    <arm_group_label>18F-FDG-PET and dw-MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female,&#xD;
&#xD;
          -  Subjects must be 18 years of age or older,&#xD;
&#xD;
          -  Histologically confirmed papillary or follicular differentiated thyroid carcinoma with&#xD;
             partial response or complete response, defined by&#xD;
&#xD;
               -  Thyroglobulin &gt; 2 μg/L under thyrotrophin stimulation, four months after at least&#xD;
                  two 131-I based treatments (3,7 GBq/100mCi or more if optimal conditions),&#xD;
&#xD;
               -  Negative extension assessment (total body bone scan, (3,7 GBq/100 mCi or more)),&#xD;
                  echography, CT scan ( neck, thorax, abdomen): no findings..&#xD;
&#xD;
          -  Patient's Informed Consent form signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of previous cancer within the least three years,&#xD;
&#xD;
          -  Performance Status &gt; 2,&#xD;
&#xD;
          -  Protected adults&#xD;
&#xD;
          -  Any medical, psychological, social or disabling conditions that could interfere or&#xD;
             jeopardize the patient's participation&#xD;
&#xD;
          -  History of allergy to radio-iodine,&#xD;
&#xD;
          -  Estimated GFR &lt; 45 ml/min /m² (MDRD method),&#xD;
&#xD;
          -  Women of childbearing potential without contraceptive method,&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus,&#xD;
&#xD;
          -  Hypersensitivity to FDG or to any radio-tracers,&#xD;
&#xD;
          -  Contraindication to administration of Thyrogen® 0.9mg&#xD;
&#xD;
          -  Intraocular foreign bodies or any metallic foreign bodies that contraindicates the&#xD;
             MRI.&#xD;
&#xD;
          -  Vascular clips, any object or implanted device that could interact with the&#xD;
             ferromagnetic field,&#xD;
&#xD;
          -  Coronary and peripheral clips, aortic stent grafts, prosthetic heart valves,&#xD;
             annuloplasty rings, vena cava filters, cardiac pacemaker, implantable cardiovascular&#xD;
             defibrillators....,&#xD;
&#xD;
          -  Implanted insulin infuser&#xD;
&#xD;
          -  Neurostimulator device&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Agitation or psychological trouble&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Vera, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrence Thyroid cancer</keyword>
  <keyword>18F-FDG PET-CT</keyword>
  <keyword>diffusion-weighted Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

